Josh Welle

Doctor of Medicine,  Toronto General - University Health Network 

Location: Africa

Consulting Services

Research Consulting Sales and Marketing Legal Support Grant Submission Career Advice and Mentoring

Areas Of Interest

Cell Line, Transformed Keratosis, Palmoplantar Ireland Receptor, Cholecystokinin B Formications Sizes, Cell Nucleus Encephalitis, Tick-Borne Connectomics Mutant Strain Mouse Guanylate Cyclase Activating Proteins Committees, Research Ethics Diacetate, Dequalinium Milk Growth Factor Aluminum Compounds Feedbacks, Audio Nucleotides, Adenine P1 Purinoceptor Basilar Artery Migraine Progressive Bulbar Palsy of Childhood Lactose Intolerance Physiology Concept, Urinary Central Catheterizations Oct-6, Octamer-Binding Protein Rectum Quince, Flowering Malted Grain Phase Desynchrony, EEG Hereditary Nonpolyposis Colon Cancer Interleukin-6 Receptor alpha Subunit Almitrine

Professional Narrative

Dr. Josh Welle was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Welle has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Assistant Professor, Harvard Med 2007
Director Medicine, Mayo Clinic 1998

Education

Doctor of medicine, Harvard Medical School 2002
Doctor of osteopathic medicine, Perelman School of Medicine 1991

Referees


Publications

Tang Z, Kong N, Zhang X, Liu Y, Hu P, Mou S, Liljeström P, Shi J, Tan W, Kim JS, Cao Y, Langer R, Leong KW, Farokhzad OC, Tao W. A materials-science perspective on tackling COVID-19. Nat Rev Mater. 2020;5(11):847-860. doi: 10.1038/s41578-020-00247-y. Epub 2020 Oct 14. PMID: 33078077; PMCID: PMC7556605.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021 Nov;178:113834. doi: 10.1016/j.addr.2021.113834. Epub 2021 Sep 4. PMID: 34492233.

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021 Feb;20(2):101-124. doi: 10.1038/s41573-020-0090-8. Epub 2020 Dec 4. PMID: 33277608; PMCID: PMC7717100.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :